Yes. It's funny that the bashers have come out again not only at the usual place but also in article comments on SA. Their cry now is "But what about Brilacidin for ABSSI? Why didn't he talk about that?"

well, maybe because a long time ago the company talked about it a lot, when they said that they were tabling the ABSSSI drug trial because the FDA massively increased the size of the clinical trial to a ludicrous 3,000 patients, at a cost of 30 million bucks to IPIX, so the management made the very wise decision to put their resources behind multiple fast clinical trials for several drugs, instead of betting the whole company on one real expensive and long clinical trial. The wisdom of that decision has been shown by the great results we've had in these multiple clinical trials.

If PYMX had not bet the farm on one drug, they might still be in business, and IPIX might not have been able to buy Brilacidin from their bankruptcy for a mere 5 million bucks. Good thing we have such smart management, isn't it?